化合物 Adavosertib|T2077|TargetMol

Adavosertib
955365-80-7

￥233 1mg 起订

￥329 2mg 起订

￥535 5mg 起订

上海更新日期：2024-12-02

TargetMol中国（陶术生物）

VIP12年

联系人：邵小姐

电话：021-021-33632979拨打

手机：15002134094 拨打

邮箱：marketing@targetmol.com

产品详情:

中文名称：: 化合物 Adavosertib

英文名称：: Adavosertib

CAS号：: 955365-80-7

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 99.58%

产品类别：: 抑制剂

货号：: T2077

Product Introduction

Bioactivity

名称	Adavosertib
描述	Adavosertib (MK-1775) is a selective inhibitor of the cell cycle regulatory protein Wee1 (IC50=5.2 nM). Adavosertib has antitumor activity that blocks the cell cycle and inhibits tumor cell proliferation.
细胞实验	Tumor cells were cultured in 96-well plates and incubated with DNA-damaging agents for 24 h, then with MK-1775 and nocodazole for additional 8 h. For p-CDC2Y15 assay, cells were lysed and subjected in a colorimetric ELISA to determine the amounts of p-CDC2Y15 (1:100) and total CDC2 (1:200). For phospho-histone H3 (pHH3), cells were fixed with methanol, stained with anti-pHH3 specific antibody and bound antibody was stained with Alexa Fluor 488 goat anti-rabbit antibody. Images were acquired with an INCell Analyzer 1000 [1].
激酶实验	Kinase reaction was conducted with 10 μmol/L ATP, 1.0 μCi of [γ-33P]ATP, and 2.5 μg of poly(Lys, Tyr) as a substrate at 30°C for 30 min. Radioactivity incorporated into the substrate was trapped on MultiScreen-PH plates and was counted on a liquid scintillation counter [1].
动物实验	Subcutaneous xenograft tumors were formed by injection of the human cancer cell lines in the hind flank of immunodeficient nude rats (F344/NJcl-rnu). To facilitate tumor formation, cells were injected in medium containing Matrigel, a solubilized basement membrane preparation extracted from the Engelbreth-Holm-Swarm mouse sarcoma. Gemcitabine, carboplatin, and cisplatin were dissolved or diluted in saline and were dosed i.v. MK-1775 was prepared in a vehicle of 0.5% methylcellulose solution and was dosed p.o. 24 h after dosing DNA-damaging agents. For efficacy studies, tumor volumes were measured with a caliper every 3 d and body weights were determined each weekday. Statistical analysis was done using repeated-measure ANOVA followed by Dunnett's test for relative tumor volume. T/C (%) was calculated as (ΔT/ΔC) × 100 if ΔT > 0 or (ΔT/TI) × 100 if ΔT < 0. ΔT was the change in mean tumor volume to the initial tumor volume for the treatment group, and ΔC was the change in mean tumor volume to the initial tumor volume for the vehicle control group. Ti was the initial tumor volume of the treatment group [1].
体外活性	方法：人结直肠癌细胞 WiDr 和人肺癌细胞 H1299 用 gemcitabine (0-100 nM) 处理 24 h，随后用 Adavosertib (30-300 nM) 处理 24 h，使用 WST-8 assay 检测细胞活力。结果：在 WiDr 细胞中，单独 gemcitabine 在细胞活力测定中的 IC50 值大于 100.0 nmol/L。Adavosertib 联合治疗显著增强了 gemcitabine 的抗生长作用。与 30 和 100 nmol/L 的 Adavosertib 共同处理将 IC50 分别降低到 21.5 和 7.1 nmol/L。在另一种 p53 缺乏型癌细胞系 H1299 中观察到 gemcitabine 的类似增强作用。[1] 方法：人肺癌细胞 H1299 和 A549 用 Adavosertib (200 nmol/L) 处理 1 h，随后后 7.5 Gy 照射 4-24 h，使用 flow cytometry 检测细胞周期。结果：在用 Adavosertib + 辐射处理的 H1299 细胞中，细胞继续进行 G2/M，没有实质性积累。与单独辐射相比，Adavosertib 基本上没有改变照射的 A549 细胞在 G2/M 中的积累。[2]
体内活性	方法：为测试体内抗肿瘤活性，用 Adavosertib (60 mg/kg，灌胃给药) 和 1 Gy 福照处理携带人肺癌肿瘤 Calu-6 的 Ncr Nu/Nu 小鼠，每天两次，持续五天。结果：药物/辐射组合显著增强了肿瘤生长延迟。当肿瘤每天两次以 1Gy 照射 5 天，并且在照射的同一天每天两次给予 60mg/kg Adavosertib 时，观察到最大的反应。[2]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 50 mg/mL (99.88 mM) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 7.4 mg/mL (14.78 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble)
关键字	Adavosertib \| AZD-1775 \| AZD 1775 \| Wee1 \| inhibit \| MK 1775 \| MK1775 \| Inhibitor
相关产品	WEE1-IN-3 \| RP-6306 \| PD173952 \| ZN-c3 \| PD 407824 \| PKMYT1-IN-3 \| ZNL 02-096 \| Debio-0123 \| PD0166285 \| GSK-1520489A
相关库	抑制剂库 \| 抗乳腺癌化合物库 \| 经典已知活性库 \| 抗癌活性化合物库 \| 已知活性化合物库 \| 激酶抑制剂库 \| 高选择性抑制剂库 \| 药物功能重定位化合物库 \| 抗癌临床化合物库 \| 抗癌药物库

MK-1775|||AZD1775|||Adavosertib (MK-1775)|TargetMol

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	(12年)
注册资本	566.2651万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,试剂,定制,服务
主营行业	化学试剂,生物活性小分子